Answers are grounded in this paper and cite their sources.
The FDA wishes to inform physicians of the removal from the market of troglitazone (Rezulin, Parke-Davis/Warner-Lambert Co, Morris Plains, NJ), a treatment for type 2 diabetes mellitus, and cisapride (Propulsid, Janssen Pharmaceutica Inc, Titusville, NJ), a treatment for severe heartburn.
No takes yet. Share an insight, caveat, or question.
Jane E. Henney (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: